目的：探讨临床使用艾迪注射液联合顺铂治疗恶性胸腔积液的临床疗效及安全性评价。方法整群选取该院2013年10月—2015年10月收治的68例肺癌恶性胸腔积液患者随机分为两组，治疗组胸腔注入顺铂和艾迪注射液同时静脉输注艾迪注射液，对照组胸腔注入顺铂；观察对比两组患者临床疗效、T细胞亚群水平变化及不良反应。结果实验组患者的有效率为73.53%，显著优于对照组的38.24%；治疗后实验组患者的T细胞亚群水平变化与治疗前差异有统计学意义，且显著高于对照组患者治疗后水平差异有统计学意义；治疗组患者的不良反应总发生率为29.41%，远低于对照组患者的64.71%。结论经临床验证，艾迪注射液联合顺铂可有效提高患者的生存质量，提高患者免疫力，且不良反应弱，即联合用药的临床效果明显优于顺铂单独用药。%Objective To observe the clinical efficacy and safety of Addie injection combined with cisplatin in the treatment of malignant pleural effusion. Methods In our hospital from October 2013 to October 2015 68 cases of lung cancer with malignant pleural effusion patients were randomly divided into two groups, treatment group and pleural injection of cisplatin and Aidi injection and intravenous injection of Aidi injection, control group intrapleural injection of cisplatin; Clinical Ob-servation on the therapeutic effect of patients in the two groups were compared, the changes of T cell subsets and adverse reactions. Results In the experimental group, the efficiency was 73.53%, was significantly better than the control group, the 38.24%; after treatment, the experimental group of patients with T cell subsets level changes and treatment no significant difference, and significantly higher than the control group patients after level; treatment group patients with adverse reac-tions of total incidence was 29.41%, far lower than that of the control group were 64.71%. Conclusion By clinical verifica-tion, Addie injection combined with cisplatin can effectively improve the quality of life of patients, improve the immunity of patients, and the adverse reaction is weak, that is, the clinical effect of combined drug is significantly better than that of cisplatin alone.
展开▼
